Recent clinical trials have showcased promising advancements in targeted therapies for small cell lung cancer (SCLC). The first-in-human Phase 1 trial of SHR-4849, an antibody-drug conjugate targeting DLL3, demonstrated encouraging outcomes for patients with relapsed SCLC. Additionally, the Phase 2 IDeate-Lung01 trial revealed that ifinatamab deruxtecan achieves high response rates in previously treated extensive-stage SCLC. These developments mark significant strides in addressing a challenging oncology subset with precision approaches targeting tumor-specific proteins.